• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Sterocort
    / Taro

    Active Ingredient

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 4 mg

    full basket chart 7180 19146

    Related information


    Posology: The dosage level depends on the nature and severity of the disease and the patient’s individual response to treatment. In general, relatively high initial doses are used, which need to be considerably higher in acute, severe forms of disease than in chronic disorders.
    Unless otherwise prescribed, the following dosage recommendations apply:
    – Active phases of systemic vasculitis:
    Polyarteritis nodosa: 32 – 80 mg/day (in patients with concomitant positive hepatitis B serology, the duration of treatment should be restricted to 2 weeks), polymyalgia rheumatica (PMR): 8 – 32 mg/day, PMR with giant cell arteritis: 32 – 64 mg/day, temporal arteritis with acute vision loss: initially high-dose intravenous pulse therapy, thereafter 64 – 80 mg/day;
    – Active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease: 32 – 80 mg/day;
    – Active rheumatoid arthritis: depending on the severity of the disease 1 – 80 mg/day. For severe progressive forms, e.g. rapidly destructive forms, 64 – 80 mg/day and/or for extra-articular manifestations 32 – 64 mg/day;
    – Spondylarthritis (ankylosing spondylitis with involvement of peripheral joints): 8 – 64 mg/day, psoriatic arthritis: 1.2 – 32 mg/day, enteropathic arthropathy with high inflammatory activity 64 – 80 mg/day;
    – Reactive forms of arthritis: 8 – 32 mg/day;
    – Arthritis in sarcoidosis: 32 – 64 mg/day;
    – Severe systemic form of juvenile idiopathic arthritis (Still’s disease) or with
    iridocyclitis refractory to topical treatment: 64 – 80 mg/day.
    Pulmonary and respiratory tract disorders
    – Bronchial asthma: Oral long-term treatment of adults: initially 32 – 64 mg/day, lower dosages (approximately 16 mg) in milder cases, maintenance dose generally 2 – 8 mg/day. Daily doses exceeding 12 mg should be avoided in long-term therapy. If oral glucocorticoids are used at doses up to about 16 mg/day, inhaled glucocorticoids should always be additionally used.
    Oral long-term treatment of severe childhood asthma: initial doses of approximately 1.6 mg/kg body weight/day may be necessary. Inhaled glucocorticoid therapy should be maintained. Systemic therapy takes place intermittently or over the longer term, once minimum requirements have been determined.
    – Oral treatment of asthma exacerbation: Adults: 16 – 32 mg/day until a stable situation (pre-exacerbation level) has been reached for at least 2 days. This is followed by a dose reduction according to the clinical course.
    Children: Approximately 0.8 mg/kg body weight/day, until a significant
    improvement occurs. This is followed by as rapid a dose reduction as possible,
    according to the clinical course;
    – Chronic obstructive pulmonary disease: for exacerbations, 16 – 32 mg/day for a maximum of 2 weeks. Long-term treatment with oral glucocorticoids is not
    – Allergic rhinitis: 4 mg/day for a maximum of 1 to 3 days.
    Adults: initially, 8 – 20 mg/day, for severe pemphigus up to 100 mg/day.
    Children: 2 – 12 mg/day; the subsequent dose reduction is guided by the course of the disease.
    Adults and children: initially 16 (-48) mg/day until onset of diuresis (generally after 7 – 10 days), maintenance dose 8 – 16 mg/day on 3 days per week.
    Method of administration: The tablets are taken whole (not chewed) with or after food with sufficient liquid. The daily dose should, if possible, be administered as a single dose in the morning (circadian therapy). However, in patients requiring high-dose therapy due to their disease, multiple daily doses are often required to achieve a maximum effect.
    The possibility of alternate-day therapy, depending on the clinical picture and the individual response, must be considered. In children and growing adolescents, treatment should preferably be on alternate days or intermittent.
    Depending on the underlying disease, clinical symptoms and response to therapy, the dose can be reduced at different rates and terminated or adjusted to the lowest possible maintenance dose, if necessary, with monitoring of the adrenal axis. In general, the dose should be kept as high and the duration of treatment as long as necessary, but also as low and as short as possible. Dose reduction should generally be gradual.
    In cases of hypothyroidism or liver cirrhosis, relatively low dosages may be sufficient or a dose reduction may be required.


    – Active phases of systemic vasculitis: Polyarteritis nodosa (in patients with concomitant positive hepatitis B serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (PMR), PMR with giant cell arteritis, temporal arteritis with acute vision loss;
    – Active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;
    – Severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive
    forms and/or with extra-articular manifestations;
    – Other forms of inflammatory rheumatic arthritis, provided that the severity of
    symptoms requires it and non-steroidal anti-inflammatory drugs (NSAIDs) cannot be used:
    Spondylarthritis (ankylosing spondylitis with involvement of peripheral joints,
    psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);
    – Reactive forms of arthritis;
    – Arthritis in sarcoidosis;
    – Severe systemic form of juvenile idiopathic arthritis (Still’s disease) or with
    iridocyclitis refractory to topical treatment.
    Pulmonary and respiratory tract disorders:
    – Bronchial asthma: For the long-term treatment of severe chronic asthma (stage 4) and for treatment of exacerbations in adults and children.
    – Chronic obstructive pulmonary disease (COPD): For short-term treatment (max. 14 days) of exacerbations;
    – Upper respiratory tract disorders: For short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.
    – Oral initial treatment of extensive, severe, acute skin conditions responsive to
    glucocorticoids, such as: Allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.
    – Minimal change glomerulonephritis;
    – Extracapillary proliferative glomerulonephritis (rapidly progressive
    glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in Goodpasture’s syndrome; for all other forms, long-term continuation of treatment;
    – Idiopathic retroperitoneal fibrosis.


    Hypersensitivity, fungal infections, administration of vaccines.

    Special Precautions

    The lowest possible dose of corticosteroid should be used to control the condition being treated. Dietary salt restriction and potassium supplementation may be necessary, especially if administered in high doses. Calcium levels should be monitored since corticosteroids increase calcium excretion. Prolonged use may produce possible damage to the optic nerves. Corticosteroids may mask some signs of infection and new infections may appear during their use. Active tuberculosis. Amebiasis, whether latent or active, should be ruled out before therapy. Pregnancy and lactation.

    Side Effects

    Fluid and electrolyte disturbances, muscle weakness, steroid myopathy, loss of muscle mass, tendon rupture, osteoporosis, vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathological fractures of long bones, peptic ulcer with possible subsequent perforation, impaired wound healing, thin fragile skin, petechiae and ecchymoses, facial erythema, increased sweating, convulsions, increased intracranial pressure with papilledema, vertigo, headache, menstrual irregularities, development of Cushingoid state, suppression of growth in children, secondary adrenocortical and pituitary unresponsiveness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetics, posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmus, negative nitrogen balance, myocardial rupture following recent myocardial infarction, anaphylactoid or hypersensitivity reactions, thromboembolism, weight gain, increased appetite, nausea, malaise, hiccups.

    Drug interactions

    See prescribing information for full details.

    Pregnancy and Lactation

    Pregnancy: Triamcinolone should not be used in the first 5 months of pregnancy, as animal studies have shown indications of teratogenic effects.
    Breastfeeding: Glucocorticoids are excreted in human milk. Breastfeeding should cease if treatment with higher doses or long-term treatment is required.
    See prescribing information for full details.

    Taro Pharmaceutical Industries